[DIAGNOSIS AND CLINICAL MANIFESTATIONS OF CIRRHOTIC CARDIOMYOPATHY]

Cirrhotic cardiomyopathy remains poorly understood in clinical settings. Prior research has shown that liver cirrhosis can affect heart function, but the exact mechanisms remain unclear. Established knowledge suggests that chronic liver disease may alter cardiac electrophysiology, yet the diagnostic criteria for this condition remain undefined. This gap motivated researchers to investigate the prevalence and features of cirrhotic cardiomyopathy in patients with liver cirrhosis. No prior work had resolved the relationship between liver disease severity and cardiac dysfunction. The study aimed to clarify how often this condition occurs and how it presents clinically. Researchers also wanted to determine if diagnostic tools like echocardiography and proBNP can detect early signs of heart damage. This work builds on existing knowledge by focusing on specific diagnostic markers and their correlation with liver cirrhosis severity.

The study aimed to explore how frequently cirrhotic cardiomyopathy occurs in patients with liver cirrhosis and to identify diagnostic features. Researchers focused on patients with alcoholic or viral liver cirrhosis who had no prior heart disease. The motivation for this work came from the lack of clear diagnostic criteria for this condition. The team wanted to determine if standard diagnostic tools could detect early signs of heart damage. They also sought to understand how the severity of liver cirrhosis affects heart function. By analyzing echocardiography, ECG, and proBNP levels, the study aimed to establish a baseline for diagnosing cirrhotic cardiomyopathy. The researchers hoped to identify patterns that could help clinicians detect heart damage in cirrhotic patients. This work could improve diagnostic accuracy and inform treatment strategies for affected individuals.

The study involved 102 patients with liver cirrhosis but no cardiovascular history. Researchers used echocardiography to assess heart structure and function. Electrocardiography was performed to detect electrophysiological abnormalities. Blood samples were collected to measure proBNP levels. The control group consisted of individuals without liver disease. Researchers compared QT interval length, proBNP levels, and signs of diastolic dysfunction between groups. Data were analyzed using statistical methods to determine significance. The severity of liver cirrhosis was assessed using the Child-Pugh classification system. These methods allowed the team to evaluate how liver disease severity correlates with heart damage.

Cirrhotic cardiomyopathy signs were detected in 65 out of 102 patients. The QT interval was significantly longer in cirrhotic patients compared to controls. ProBNP levels averaged 540.85 pg/ml in cirrhotic patients versus 89.45 pg/ml in healthy individuals. Diastolic dysfunction was observed in 55.6% of patients. The incidence of CCMP increased with Child-Pugh class severity. In class A patients, 42.4% showed CCMP signs, while 100% of class C patients did. Alcoholic liver cirrhosis showed more pronounced CCMP features than viral. ProBNP emerged as the most sensitive marker of heart damage in cirrhotic patients.

The study found that cirrhotic cardiomyopathy occurs in 63.7% of cirrhotic patients. Researchers observed that CCMP signs worsen with liver disease severity. The QT interval and proBNP levels increased progressively with Child-Pugh class. Diastolic dysfunction was more common in severe cirrhosis cases. Alcoholic liver cirrhosis showed more pronounced CCMP features than viral. ProBNP proved to be the most reliable indicator of heart damage in cirrhotic patients. The findings suggest that routine cardiac evaluations may be necessary for cirrhotic patients. The authors propose that proBNP testing could improve early detection of heart damage in this population.